Neuropeptide Changes in Inflammatory Bowel Disease — VIP Down, Substance P Receptors Up

What the researchers found

VIP is diminished in intestinal smooth muscle of Crohn's patients. Substance P receptors are markedly increased at small vessels and lymph nodules in inflamed IBD intestine.

Why it matters

If neuropeptides actively drive IBD symptoms like abnormal gut motility and inflammation, they could be targets for new treatments that go beyond standard immune suppression.

How the study worked

Review of studies examining gut neuropeptide content, innervation patterns, and receptor distribution in tissue from IBD patients.

What this study cannot tell us

Review article summarizing available evidence as of 1991. The field was still early, and not all findings had been replicated. Neuropeptide measurement techniques were evolving.

How to read the evidence

Moderate-quality review synthesizing available evidence from tissue studies. Individual studies had varying quality.

When this study was published

Published in 1991. Neuropeptide involvement in IBD has been extensively confirmed and expanded since.

The bigger picture

If neuropeptide changes actively drive IBD symptoms, they represent therapeutic targets beyond standard immune suppression. This concept has influenced the development of peptide-targeted therapies for IBD and other gut disorders.

Questions still open

• Could VIP replacement therapy improve Crohn's motility symptoms?
• Are substance P receptor antagonists useful for IBD treatment?

Common questions

Read the original research

Neuropeptides and inflammatory bowel disease.

Zeitschrift fur Gastroenterologie. Verhandlungsband, 26, 253-7

Citation

Eysselein, V E; Nast, C C. (1991). Neuropeptides and inflammatory bowel disease.. Zeitschrift fur Gastroenterologie. Verhandlungsband, 26, 253-7.